Trial Profile
A Phase 1 Study of SGN-CD48A in Patients With Relapsed or Refractory Multiple Myeloma
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 28 Oct 2020
Price :
$35
*
At a glance
- Drugs SGN-CD48A (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Seagen
- 16 Sep 2019 Status changed from active, no longer recruiting to discontinued.
- 26 Jun 2019 Planned End Date changed from 1 Dec 2021 to 1 Oct 2019.
- 26 Jun 2019 Planned primary completion date changed from 1 Aug 2020 to 1 Oct 2019.